inotrem

Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock.

Total raised

€58M

€58,000,000

Funding rounds

Investors

distinct backers

Active since

2019-09

latest 2020-12

Funding by year

EUR raised per year

High confidence

Raise-next likelihood9

base rate 30% for Other

Exit likelihood16

base rate 12% (2+ rounds)

Timing: dormant vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.

2 rounds

Date	Stage	Amount	Investors
2020-12-02	Other	€19M	Fountain Healthcare Partners	View deal →
2019-10-01	Series B	€39M	Invus,Morningside Group	View deal →

same sector or country